• 제목/요약/키워드: Breast cancer cases

검색결과 627건 처리시간 0.024초

다발성 악성종양에 동반된 폐암의 임상 특징과 변이형 p53 발현 (Clinical Characteristics and Abnormal p53 Expression of Lung Cancer Associated with Multiple Primary Cancer)

  • 신창진;박혜정;신경철;심영란;정진홍;이관호
    • Tuberculosis and Respiratory Diseases
    • /
    • 제47권3호
    • /
    • pp.331-338
    • /
    • 1999
  • 연구배경: 악성종양에 대한 진단 및 치료방법의 발전으로 악성종양 환자의 생존기간이 연장되고, 생존율 또한 과거보다 높아졌다. 또한 수술적 절제술로 악성종양을 제거한 환자 중 약 10% 정도는 약 10년이내 속발성 원발성 종양이 생긴다고 알려지고 있다. 그래서 다발성 원발성 악성종양의 원인과 위험 인자 및 조기 진단은 매우 중요한 일이다. 저자들은 다발성 원발성 악성종양에 병발한 폐암과 원발성 폐암의 임상적 특징과 p53 종양 억제 유전자 변이에 의한 변이형 p53 발현율을 조사하여 두 질환사이의 차이를 비교해 보았다. 방법: Moertel의 다발성 원발성 악성 종양의 분류에 적합한 환자 중 폐암이 동반된 20례(비소세포암 16례, 소세포암 4례)와 비교군으로 원발성 비소세포암 26례를 대상으로 변이형 p53 발현율을 면역조직화학 염색법을 이용하여 조사하였다. 곁과: 폐암과 동반된 악성종양은 위암이 8례로 가장 많았고, 식도암, 폐암, 대장암이 각각 2례 이었으며, 후두암, 방광암, 간암, 유방암, 부신암, 소장암이 각각 1례 이었다. 다발성 원발성 악성종양과 병발한 비소세포암과 원발성 비소세포암의 남녀비는 각각 7:1, 2.7:1 이었고, 흡연력은 각각 16례 중 15례, 26례 중 19례가 있었다. 다발성 원발성 악성종양에 병발한 비소세포암은 원발성 비소세포암에 비해 임상적 병기가 비교적 균등하였으며(p<0.05), 조직학적 분화도는 나쁜 경우가 많은 경향이었다(p>0.05). 다발성 원발성 악성종양에 병발한 비소세포암과 원발성 비소세포암의 변이형 p53 각각 62.5%, 76.7%로 유의한 차이는 없었다(p>0.05). 결론: 다발성 원발성 악성종양에 병발한 비소세포암의 변이형 p53 단백 발현율은 차이가 없었다. 변이형 p53 단백 염색법은 다발성 원발성 악성종양에 병발한 비소세포암과 원발성 비소세포암을 구별하는데 유용성을 인정할 수 없었다.

  • PDF

Evaluation of electron dose distribution obtained from ADAC Pinnacle system against measurement and Monte Carlo method for breast patients

  • Lee, S.;Lee, R.;Park, D.;S. Suh
    • 한국의학물리학회:학술대회논문집
    • /
    • 한국의학물리학회 2003년도 제27회 추계학술대회
    • /
    • pp.82-82
    • /
    • 2003
  • Introduction: With the development of dose calculation algorithms for electron beams, 3D RTP systerns are available for electron beam dose distribution commercially. However, no studies evaluated the accuracy of dose calculation with ADAC Pinnacle system for electron beams. So, the accuracy of the ADAC system is investigated by comparing electron dose distributions from ADAC system against the BEAMnrc/DOSXYZnrc. Methods: A total of 33 breast cancer patients treated with 6, 9, and 12MeV electrons in our institution was selected for this study. The first part of this study is to compare the dose distributions of measurement, TPS and the BEAMnrc/DOSXYZnrc code in flat water phantom at gantry zero position and for a 10 ${\times}$ 10 $\textrm{cm}^2$ field. The second part is to evaluate the monitor unit obtained from measurement and TPS. Adding actual breast patient's irregular blocks to the first part, monitor units to deliver 100 cGy to the dose maximum (dmax) were calculated from measurement and 3D RTP system. In addition, the dose distributions using blocks were compared between TPS and the BEAMnrc/DOSXYZnrc code. Finally, the effects of tissue inhomogeneities were studied by comparing dose distributions from Pinnacle and Monte Carlo method on CT data sets. Results: The dose distributions calculated using water phantom by the TPS and the BEAMnrc/ DOSXYZnrc code agreed well with measured data within 2% of the maximum dose. The maximum differences of monitor unit between measured and Pinnacle TPS in flat water phantom at gantry zero position were 4% for 6 MeV and 2% for 9 and 12 MeV electrons. In real-patient cases, comparison of depth doses and lateral dose profiles calculated by the Pinnacle TPS, with BEAMnrc/DOSXYZnrc code has generally shown good agreement with relative difference less than +/-3%. Discussion: For comparisons of real-patient cases, the maximum differences between the TPS and BEAMnrc/DOSXYZnrc on CT data were 10%. These discrepancies were due in part to the inaccurate dose calculation of the TPS, so that it needs to be improved properly. Conclusions: On the basis of the results presented in this study, we can conclude that the ADAC Pinnacle system for electron beams is capable of giving results absolutely comparable to those of a Monte Carlo calculation.

  • PDF

Lymphoscintigraphy와 전초 림프절 절제술을 이용한 피부 악성종양의 치험례 (Lymphoscintigraphy for Intraopertive Sentinel Node Biopsy of Skin and Soft Tissue Malignancy)

  • 이태훈;심정수;정재호
    • Archives of Plastic Surgery
    • /
    • 제32권5호
    • /
    • pp.635-640
    • /
    • 2005
  • Sentinel lymphnode biopsy is widely performed in the management of malignant melanoma and breast cancer. The sentinel lymphnode is the prime site of draining from the malignant lesion and of metastasis. The aim of this study was to evaluate a usefulness of lymphoscintigraphy in conjunction with a removal of sentinel lymphnodes of skin and soft tissue malignancy. We studied 11 patients selected between January, 2003 and November, 2004. Clinically sentinel lymphnodes free of metastasis were examined with lymphoscintigraphy, gamma detection probe and vital dye staining, and we reviewed histopathologic findings and inert status of the nodes and the results fo treatment. Nine cases were malignant melanoma, one was squamous cell carcinoma on the left hand and another one leiomyosarcoma. Sentinel lymphnodes were identified in all cases. Three cases of malignant melanoma had positive sentinel lymphnodes on histological examination. All patients with positive sentinel lymphnodes were treated with therapeutic regional lymphadectomy, chemotherapy and adjuvant regimen. Four patients underwent PET scanning and followed sentinel lymphnode biopsy. Two had no metastasis signs on PET scanning. Therapeutic lymphnode dissection was carried out upon the patients whose sentinel lymphnode was positive on PET scanning. We contend that lymphoscintigraphy and sentinel lymphnode biopsy are reliable to confirm regional lymphnode metastasis of the skin and soft tissue malignancy, and blind extensive lymphnode dissection can be spared.

Clinical Features of Multiple Primary Malignancies: a Retrospective Analysis of 72 Chinese Patients

  • Jiao, Feng;Yao, Li-Juan;Zhou, Jin;Hu, Hai;Wang, Li-Wei
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권1호
    • /
    • pp.331-334
    • /
    • 2014
  • There is a scarcity of reports addressing patients with multiple primary malignancies (MPM), especially for Chinese cses. The aim of this study was to present a detailed analysis of Chinese patients presenting with at least two primary malignancies. Particularly, the clinical characteristics and survival between synchronous and metachronous MPM were compared. Out of 6,545 cases, 72 patients (1.1%) including 39 males (54.2%) and 33 females (45.8%) were diagnosed as MPM, giving a male: female sex ratio of 1.2:1. Of these, there were 16 (22.2%) cases of synchronous MPM (7 males, 9 females), 55(76.4%) metachronous (31 males, 24 females), and 1 "mixed form". For first tumor diagnosis time, synchronous MPM patients generally presented later than the metachronous cases. The top three sites for malignancies with metachronous MPM were colorectum, head and neck, and lung, while for synchronous they were lung, colorectum and breast. Among MPM patients, the median survival time was 15.7 years and the 5-year survival was 56%, and there was statistical difference in MPM categories (P < 0.05). The median survival time was 17.3 years and 3.8 years for metachronous and synchronous MPM patients, respectively. In comparison with synchronous MPM patients, those metachronous had a longer survival. This studies increase understanding of the clinical features of Chinese MPM patients and suggest that those presenting with metachronous cancers have a higher incidence and a better prognosis.

Role of CD10 Immunohistochemical Expression in Predicting Aggressive Behavior of Phylloides Tumors

  • Tariq, Muhammad Usman;Haroon, Saroona;Kayani, Naila
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권8호
    • /
    • pp.3147-3152
    • /
    • 2015
  • Background: Phylloides tumors are rare breast neoplasms with a variable clinical course depending on the tumor category. Along with histologic features, the role of immunohistochemical staining has been studied in predicting their behavior. Objectives: Our aim was to evaluate the role of CD 10 immunohistochemical staining in predicting survival, recurrence and metastasis in phylloides tumor. We also evaluated correlations of other clinicopathological features with overall and disease-free survival. Materials and Methods: CD10 expression was studied in 82 phylloides tumors divided into recurrent/metastatic and non-recurrent/non-metastatic cohorts. The Chi-square test was applied to determine the significance of differences in CD10 expression between outcome cohorts. Uni and multivariate survival analyses were also performed using log-rank test and Cox regression hazard models. Results: All 3 metastatic cases, 5 out of 6 (83.3%) recurrent cases and 37out of 73 (50.7%) non-recurrent and non-metastatic cases expressed significant (2+ or 3+) staining for CD10. This expression significantly varied between outcome cohorts (p<0.03). Tumor category and histological features including mitotic count and necrosis correlated significantly with recurrence and metastasis. A significant decrease in overall and disease free survival was seen with CD10 positivity, malignant category, increased mitoses and necrosis. Neither CD10 expression nor any other clinicopathologic feature proved to be an independent prognostic indicator in multivariate analysis. Conclusions: CD10 immunohistochemical staining can be used as a predictive tool for phylloides tumor but this expression should be interpreted in conjunction with tumor category.

UHRF2 mRNA Expression is Low in Malignant Glioma but Silencing Inhibits the Growth of U251 Glioma Cells in vitro

  • Wu, Ting-Feng;Zhang, Wei;Su, Zuo-Peng;Chen, San-Song;Chen, Gui-Lin;Wei, Yong-Xin;Sun, Ting;Xie, Xue-Shun;Li, Bin;Zhou, You-Xin;Du, Zi-Wei
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권10호
    • /
    • pp.5137-5142
    • /
    • 2012
  • UHRF2 is a member of the ubiquitin plant homeo domain RING finger family, which has been proven to be frequently up-regulated in colorectal cancer cells and play a role as an oncogene in breast cancer cells. However, the role of UHRF2 in glioma cells remains unclear. In this study, we performed real-time quantitative PCR on 32 pathologically confirmed glioma samples (grade I, 4 cases; grade II, 11 cases; grade III, 10 cases; and grade IV, 7 cases; according to the 2007 WHO classification system) and four glioma cell lines (A172, U251, U373, and U87). The expression of UHRF2 mRNA was significantly lower in the grade III and grade IV groups compared with the noncancerous brain tissue group, whereas its expression was high in A172, U251, and U373 glioma cell lines. An in vitro assay was performed to investigate the functions of UHRF2. Using a lentivirus-based RNA interference (RNAi) approach, we down-regulated UHRF2 expression in the U251 glioma cell line. This down-regulation led to the inhibition of cell proliferation, an increase in cell apoptosis, and a change of cell cycle distribution, in which S stage cells decreased and G2/M stage cells increased. Our results suggest that UHRF2 may be closely related to tumorigenesis and the development of gliomas.

전이성 병적 골절 또는 병적 임박 골절의 수술적 치료 (Surgical Treatment of Metastatic Pathologic or Impending Pathologic Fractures)

  • 김갑중;이상기;최원식;서동욱
    • 대한골관절종양학회지
    • /
    • 제15권1호
    • /
    • pp.44-51
    • /
    • 2009
  • 목적: 전이성 병적 골절 또는 병적 임박 골절로 진단받고 수술을 시행한 환자의 결과를 분석하고자 하였다. 대상 및 방법: 2004년 1월부터 2007년 12월까지 전이성 병적 골절 또는 병적 임박 골절로 진단받고 수술적 치료를 시행한 18환자, 19예를 대상으로 하였다. 남자가 6예 여자가 12예였으며 평균 나이는 65.1세였다. 평균 추시 기간은 15.2개월이였다. 초기 진단으로 병적 골절이 14예, 병적 임박 골절이 5예였다. 기능적 평가는 추시 중에 MSTS 점수를 측정하였으며 주기적인 방사선 촬영을 통해 방사선학적 결과를 분석하였으며 수술 후 합병증 유 무를 분석하였다. 결과: 원발암은 다발성 골수종 6예, 신 세포암 4예, 담관암 2예, 대장암 2예, 유방암 2예 및 평활근 육종이 2예였다. 전이 병소는 대퇴골이 10예, 쇄골 4예, 상완골 2예, 경골 2예, 요골 1예였다. 수술 방법으로 소파술, 시멘트 충전술, 내고정술 및 관절 성형술을 시행하였다. 평균 MSTS 점수는 15.9였다. 수술 후 합병증으로는 감염이 1예, 국소 재발이 1예, 고정물의 이완이 1예 있었다. 최종 추시 시 유병 상태 10명, 사망 8명이었다. 결론: 전이성 병적 골절 및 병적 임박 골절의 수술적 치료는 하지의 경우 조기 보행을 가능하게 하고 상지의 기능 숙달도에 만족할 만할 결과를 보이며, 이환 부의의 통증 조절과 환자의 정서적 만족도에 매우 우수한 결과를 보였다. 환자의 남은 여생 삶의 질 향상에 필요한 술식이라 사료된다.

  • PDF

Projection of Burden of Cancer Mortality for India, 2011-2026

  • Dsouza, Neevan D.R.;Murthy, N.S.;Aras, R.Y.
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권7호
    • /
    • pp.4387-4392
    • /
    • 2013
  • Projection of load of cancer mortality helps in quantifying the burden of cancer and is essential for planning cancer control activities. As per our knowledge, there have not been many attempts to project the cancer mortality burden at the country level in India mainly due to lack of data on cancer mortality at the national and state level. This is an attempt to understand the magnitude of cancer mortality problem for the various calendar years from 2011 to 2026 at 5-yearly intervals. Age, sex and site-wise specific cancer mortality data along with populations covered by the registries were obtained from the report of National Cancer Registry Programme published by Indian Council of Medical Research for the period 2001-2004. Pooled age sex specific cancer mortality rates were obtained by taking weighted average of these six registries with respective registry populations as weights. The pooled mortality rates were assumed to represent the country's mortality rates. Populations of the country according to age and sex exposed to the risk of cancer mortality in different calendar years were obtained from the report of Registrar General of India providing population projections for the country for the years from 2011 to 2026. Population forecasts were combined with the pooled mortality rates to estimate the projected number of cancer mortality cases by age, sex and site of cancer at various 5-yearly periods Viz. 2011, 2016, 2021 and 2026. The projections were carried out for the various cancer-leading sites as well as for 'all sites' of cancer. The results revealed that an estimated 0.44 million died due to cancer during the year 2011, while 0.51 million and 0.60 million persons are likely to die from cancer in 2016 and 2021. In the year 2011 male mortality was estimated to be 0.23 million and female mortality to be 0.20 million. The estimated cancer mortality would increase to 0.70 million by the year 2026 as a result of change in size and composition of population. In males increase will be to 0.38 millions and in females to 0.32 millions. Among women, cancer of the breast, cervical and ovary account for 34 percent of all cancer deaths. The leading sites of cancer mortality in males are lung, oesophagus, prostrate and stomach. The above results show a need for commitment for tackling cancer by reducing risk factors and strengthening the existing screening and treatment facilities.

전이성 피부 샘암종의 면역조직화학적 고찰 (Metastatic Adenocarcinoma of the Skin - Immunohistochemical Study)

  • 최금하;장규윤
    • 동의생리병리학회지
    • /
    • 제23권5호
    • /
    • pp.1041-1048
    • /
    • 2009
  • The development of skin metastasis is usually a morbid prognostic feature although they occur infrequently. Adenocarcinomas account for up to about 70% of all metastatic skin cancer. In general, adenocarcinomas are the most difficult metastatic tumor to accurately identify the primary site because they don't have distinctive histological features. For this reason, immunohistochemistry have been used to help identify the origin of metastatic adenocarcinomas. This study performed immunohistochemical staining with metastatic adenocarcinomas of the skin using a variety of antisera to find out characteristic immunohistochemical findings of them. This study was made upon the 29 cases of metastatic adenocarcinomas of the skin, which had been confirmed histopathologically in Chonbuk National University Hospital from January, 1986 to April, 2006, Paraffin blocks were colledted and homemade tissue arrays were made. We performed immunohistochemical staning using 12 antibodies (MUC1, 2, 5AC, 6, cytokeratin (CK) 7, 20, thyroid transcription factor-1 (TTF-1), estrogen receptor (ER), progesterone receptor (PR), beta-catenin, cox-2, claudin-1). The mean age at the time of diagnosis was 60.7 years and the male to female ratio was 1.2:1.0. The most common primary site was lung, followed by stomach and colorectum. MUC1 was expressed by most colorectal, breast and lung adenocarcinoma. MUC2 was expressed infrequently. MUCSAC was expressed by most gastric and colorectal cancer MUC6 was not specific of any primary site in this series. CK7+/CK20+immunophenotype was observed in gastric, lung, colorectal adenocarcinoma. CK7+/CK20- immunophenotype was observed in breast, lung, endometrial, uterine cervical, bile duct adenocarcinoma, while CK7-/CK20+ immunophenotype was observed only in colorectal adenocarcinoma. This results show the utility of TTF-1 to confirm the pulmonary origin. On the other hand ER and PR were not useful markers to assess the origin of primary tumor in this series.

대장 선종 이형성 및 대장암과 임신, 출산, 월경 요인의 관련성에 관한 환자-대조군 연구 (A Case-control Study of the Relationships between Reproductive Factors and Degree of Dysplasia of the Colorectal Adenoma and Cancer)

  • 이세영;최규용;김미경;이진희;맹광호;이원철
    • Journal of Preventive Medicine and Public Health
    • /
    • 제36권3호
    • /
    • pp.279-288
    • /
    • 2003
  • Objectives : Evidence for an effect of rerroductive factors on colorectal carcinogenesis is not yet consistent. Little research has been conducted to investigate whether reproductive factors were associated with colorectal adenomas that are the precursors of colorecta1 cancer, We evaluated the relationships between reproductive factors and the degree of dysplasia of the colorectal adenoma and cancer as colorectal adenoma-carcinoma sequence. Methods : For this study, 241 adenoma cases with histopathologically confirmed incident colorectal adenoma, 76 cancer cases with colorectal cancer and 1677 controls were collected from Our Lady of Mercy Hospital, The Catholic University of Korea, during 1994-1999. Before colonoscopy, information on demographic characteristics, reproductive factors, life style habits and dietary intake were obtained by interviewed questionnaire. Adjusted OR and 95% CI were estimated by using polytomous logistic regression model, Potential confounders that were selected based on the goodness of fit Statistics and interaction between risk factors were considered in this adjustment. The Wald statistic was calculated to test the heterogeneity of the odds ratios for each case. Results .: Postmenopausal women with natural menopause were found to be positively associated with the risk of mild dysplasia adenoma (multivariate-adjusted OR : 2.59, 95% CI=1.1-0.2). Parity was found to be negatively associated with the risk of colorectal lancer (age-adjusted OR : 0.40, 95% CI=0.2-0.9), but did not significantly decrease the risk of colorectal cancer (multivariate-adjusted OR : 0.95, 95% CI=0.3-2.9). Me associations were seen between a9e at menarche, breast feeding, induced abortion, oral contraceptive use, menopausal types, menopausal age or hormone replacement therapy (HRT and the degree of dysplasia of the colorectal adenoma and cancer. However, none of these associations differed' significantly between the degree of dysplasia of the colorectal adenoma and cancer. Conclusions : These findings suggest that postmenopausal women with natural menopause may experience increased risk of mild dysplasia adenorna among colorectal adenoma-carcinoma sequence.